Trastuzumab deruxtecan (T-DXd, DS-8201a), CAS: 1826843-81-5, is an antibody-drug conjugate (ADC) for HER2-positive cancers. It combines the anti-HER2 monoclonal antibody trastuzumab with the cytotoxic agent deruxtecan (DXd). Trastuzumab binds to HER2, a protein overexpressed on cancer cells, and delivers deruxtecan directly to the tumor. Deruxtecan inhibits DNA replication, leading to cancer cell death. T-DXd is used primarily to treat HER2-positive breast cancer and other HER2-expressing solid tumors.
Key Features:
- HER2 Targeting: Trastuzumab specifically binds to HER2 on tumor cells, ensuring precise delivery of deruxtecan.
- Cytotoxic Agent (Deruxtecan/DXd): Deruxtecan inhibits DNA replication, which kills cancer cells.
- Linker Technology: The stable linker ensures controlled release of deruxtecan inside the tumor cells.
Applications:
- Cancer Treatment: Targets and kills HER2-positive cancer cells, especially in breast cancer and other solid tumors.
- Targeted Therapy: Delivers deruxtecan directly to cancer cells, minimizing harm to healthy tissue.
- Monoclonal Antibody Therapy: Provides an effective treatment for patients with HER2-expressing tumors, offering a more targeted chemotherapy approach.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.